Confirmed Objective Response Rate

In DESTINY-Breast03, a head-to-head study vs T-DM1,

ENHERTU delivered nearly 83% confirmed ORR, more than double the 36.1% T-DM1 response1,2,a

Secondary endpoint: Confirmed objective response rate per BICR

Bar chart depicting in DESTINY-Breast03 that ENHERTU demonstrated a confirmed ORR of 82.7% (n=205/248; 95% CI: 77.4, 87.2); 15.7% CR (n=39) + 66.9% PR (n=166) and T-DM1 ORR was 36.1% (n=87/241; 95% CI: 30.0, 42.5) 8.3% CR (n=20) + 27.8% PR (n=67). Bar chart depicting in DESTINY-Breast03 that ENHERTU demonstrated a confirmed ORR of 82.7% (n=205/248; 95% CI: 77.4, 87.2); 15.7% CR (n=39) + 66.9% PR (n=166) and T-DM1 ORR was 36.1% (n=87/241; 95% CI: 30.0, 42.5) 8.3% CR (n=20) + 27.8% PR (n=67).

ENHERTU
(n=248)
T-DM1
(n=241)
CR, % (n) 15.7 (39) 8.3 (20)
PR, % (n) 66.9 (166) 27.8 (67)
SD, % (n) 14.9 (37) 40.2 (97)
PD, % (n) 1.2 (3) 17.8 (43)
NE, % (n) 1.2 (3) 5.8 (14)
DCR (CR+
PR+SD), % (n)
97.5 (242) 76.3 (184)
  • 99% of patients did not progress on treatment
  • ~98% of patients had disease control (CR+PR+SD)
  • ORR was not tested for statistical significance and not powered to show differences between treatment arms

Nearly every patient (~98%) in the ENHERTU arm experienced a response from treatment

aAnalysis was performed based on the patients with measurable disease assessed by BICR at baseline (n=248 patients randomized to receive ENHERTU; n=241 for T-DM1).1

Downloadable Resource for You:

    Take a closer look at the DESTINY-Breast03
    efficacy and safety data

BICR, blind independent central review; CI, confidence interval; CR, complete response; DCR, disease control rate; HER2, human epidermal growth factor receptor 2; mBC, metastatic breast cancer; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; T-DM1, ado-trastuzumab emtansine.